Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-41466
Titel: Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker
VerfasserIn: Burgard, Caroline
Engler, Jakob
Blickle, Arne
Bartholomä, Mark
Maus, Stephan
Schaefer-Schuler, Andrea
Khreish, Fadi
Ezziddin, Samer
Rosar, Florian
Sprache: Englisch
Titel: Frontiers in Medicine
Bandnummer: 10
Verlag/Plattform: Frontiers
Erscheinungsjahr: 2024
Freie Schlagwörter: PSMA—prostate-specific membrane antigen
PET/CT
radioligand therapy
prostate cancer
dual imaging
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Purpose: The value of [18F]fluorodeoxyglucose ([18F]FDG) PET/CT in monitoring prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) is still unclear. The aim of this study was to identify appropriate prognostic dynamic parameters derived from baseline and follow-up [18F]FDG and dual [18F] FDG/[68Ga]Ga-PSMA-11 PET/CT for monitoring early non-responding mCRPC patients undergoing PSMA-RLT. Methods: Twenty-three mCRPC patients of a prospective registry (NCT04833517), who were treated with [177Lu]Lu-PSMA-617 RLT and classified as early non-responders were included in this study. All patients received dual PET/ CT imaging with [18F]FDG and [68Ga]Ga-PSMA-11 at baseline and after median two cycles of RLT. We tested potential biomarkers representing the “change of glucometabolic activity (cGA)” and “change of glucometabolic activity in relation to PSMA expression (cGAP)” composed of established parameters on [ 18F]FDG PET/CT as SUVmax, cumulative SUV of five lesions (SUV5), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) and its corresponding parameters on [68Ga]Ga-PSMA-11 PET/CT, respectively, for association with overall survival (OS). Results: Kaplan–Meier analyses showed no significant association with OS for each tested cGA (cGASUVmax p =  0.904, cGASUV5, p =  0.747 cGAMTV p =  0.682 and cGATLG p =  0.700), likewise the dual imaging biomarkers cGAPSUVmax (p =  0.136), cGAPSUV5 (p =  0.097), and cGAPTV (p =  0.113) failed significance. In contrast, cGAPTL, which is based on TLG and total lesion PSMA (TLP) showed a significant association with OS (p =  0.004). Low cGAPTL (cut-off 0.7) was associated with significant longer survival (17.6 vs. 12.9  months). Conclusion: The novel biomarker cGAPTL, which represents the temporal change of whole-body TLG normalized by TLP, predicts overall survival in the challenging cohort of patients non-responding to PSMA-RLT.
DOI der Erstveröffentlichung: 10.3389/fmed.2023.1339160
URL der Erstveröffentlichung: https://doi.org/10.3389/fmed.2023.1339160
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-414663
hdl:20.500.11880/37151
http://dx.doi.org/10.22028/D291-41466
ISSN: 2296-858X
Datum des Eintrags: 22-Jan-2024
Bezeichnung des in Beziehung stehenden Objekts: Supplementary material
In Beziehung stehendes Objekt: https://ndownloader.figstatic.com/files/44075495
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Radiologie
Professur: M - Prof. Dr. Samer Ezziddin
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
fmed-10-1339160.pdf1,64 MBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons